Photo via The Independent

US approves cheap generic version of breakthrough HIV prevention jab – in major step towards ending Aids

Read the original at The Independent ↗
Cite

Trew, B. (2026, November 2). US approves cheap generic version of breakthrough HIV prevention jab – in major step towards ending Aids. The Independent. https://www.independent.co.uk/news/world/americas/us-hiv-aids-lenacapavir-fda-approval-jab-b3077695.html

Dated from the outlet's own feed. Check the original for its byline.

The Independent · collected 2026-11-02 · by Bel Trew

Quick Summary

The FDA has approved the first generic version of Lenacapavir, a twice-yearly HIV prevention injection, developed by India’s Dr Reddy’s Laboratories. This generic drug will cost just $40 per person annually and be distributed in 120 low- and middle-income countries, compared to Gilead Sciences’ original price tag of over $28,000 per year. The rapid approval process, completed within 16 months, marks a significant step toward the global goal of ending AIDS by 2030, with Zambia expected to be the first country to receive supplies.
Written by AI on 2026-11-02, from this article's own text only (the story summary below draws on all the coverage).
See how they differ ↓

AI analysis

Story summary

The US Food and Drug Administration (FDA) has approved a generic version of lenacapavir, a twice-yearly HIV prevention injection, making it available for just $40 per person annually in 120 low- and middle-income countries. Developed by India’s Dr Reddy’s Laboratories under an agreement brokered by Unitaid and other health initiatives, this development is seen as a significant step towards ending the AIDS epidemic by 2030. The original drug, made by Gilead Sciences, costs over $28,000 per year in the US, highlighting the generic's affordability for those most affected. Zambia is expected to be among the first countries to receive the supplies, raising hopes of significantly reducing HIV infections through more accessible and convenient preventive measures.

Written for “FDA Approves Cheap HIV Prevention Shot” on 2026-11-22, grounded in this article and the 2 other(s) covering the same event.

How they differ

3 outlets covered “FDA Approves Cheap HIV Prevention Shot”.

What each outlet says

One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.

The IndependentThis outlet2 Nov

The FDA has approved the first generic version of Lenacapavir, a twice-yearly HIV prevention injection, developed by India’s Dr Reddy’s Laboratories. This generic drug will cost just $40 per person annually and be distributed in 120 low- and middle-income countries, compared to Gilead Sciences’ original price tag of over $28,000 per year. The rapid approval process, completed within 16 months, marks a significant…

US approves cheap generic version of breakthrough HIV prevention jab – in major step towards ending Aids (this article)
CBC2 Nov

The U.S. Food and Drug Administration has approved a generic version of lenacapavir, a twice-annual HIV-prevention shot, expected to cost $40 US per person annually in 120 low- and middle-income countries. This development aims to enhance accessibility compared to the brand-name version priced at $28,218 US per year in the U.S., making it more affordable and convenient for those at high risk of HIV infection. The…

Cheap version of HIV-prevention shot raising hope in low-income countries →
Semafor4 Nov

US regulators have given tentative approval to a generic version of lenacapavir, a long-acting HIV prevention injection that will cost $40 per person annually in 120 low- and middle-income countries. This development is seen as potentially crucial for regions like Africa where funding cuts have impacted HIV-prevention programs. The approval aims to make the drug more accessible and could significantly contribute to…

FDA grants tentative approval to low-cost HIV shot →

Compared with similar articles

This article reads leans left and hedges 13% of its claims. Each row says how that neighbour differs.
CBC News
Hedges 4 of 40 claims Outlet record 60/100
Semafor
Leans left Hedges 2 of 5 claims Outlet record 64/100

Story

FDA Approves Cheap HIV Prevention Shot
Health · 3 article(s) covering the same event. See how they differ ↑
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
31
sentences that state something as happening or true
Uncertain
13%
4 of 31 hedged ("reportedly", "may", "according to")
Leaning
Leans left
of the writing, not the subject · beta estimate
Publisher signals
59/100
The Independent's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
3
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-11-02 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

The Independent · 4810 article(s) · 10 correction(s) detected
Running correction rate · 10 correction(s)

Who wrote this

Bel Trew
9 article(s) here · 1 carrying a prediction
Warning readers may find some of this content distressing For the last six months Aisha*, 59, has been plagued by recurring visions of her murdered son talking to her. She cannot sleep or think clearly, she says, stumbling to a halt.
An estimated 825,000 children under five are expected to suffer from severe acute malnutrition in 2026.
An estimated 825,000 children under five are expected to suffer from severe acute malnutrition in 2026.
Warning readers may find some of this content distressing For the last six months Aisha*, 59, has been plagued by recurring visions of her murdered son talking to her. She cannot sleep or think clearly, she says, stumbling to a halt.
The United Nations believes Lenacapavir, which is made by US pharmaceutical giant Gilead Sciences, could be key to reaching the goal of ending the Aids epidemic by 2030.
The UN’s highest investigative body then launched a probe in early 2024 which ultimately concluded nine of the 19 staff accused by Israel “may have been involved” in October 7 but added “it was not able to independently authenticate information used by Israel to support the allegations”.
The brief concluded that Israel’s policies, ultimately aimed “at preventing the establishment of a Palestinian state”, will “drive the security situation in the Palestinian territories toward an explosion, which is a danger for the entire region”.
Also by Bel Trew
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 9 articles by Bel Trew →

Topics

FDA Gilead Lenacapavir The US Food and Drug Administration Unitaid

Subjects

FDA ORG · 6× Gilead ORG · 5× Unitaid ORG · 5× Independent ORG · 2× Pérez Casas PERSON · 2× Zambia GPE · 2× Gilead Sciences ORG · 1× India GPE · 1× The US Food and Drug Administration ORG · 1× The United Nations ORG · 1×

Narrative

The generic, developed by India’s Dr Reddy’s Laboratories, will cost just $40 per person per year and be made available in 120 low- and middle-income countries under an existing partnership agreement brokered by global health initative Unitaid, the Clinton Health Access Initiative and Wits RHI, a health research institute in Africa.
framing: assertive · carried by 1 article(s) · first seen 2026-11-02
The United Nations believes Lenacapavir, which is made by US pharmaceutical giant Gilead Sciences, could be key to reaching the goal of ending the Aids epidemic by 2030.

Claims (31 extracted, 4 hedged)

The US Food and Drug Administration (FDA) has approved the first generic version of Lenacapavir, the twice-yearly HIV prevention jab described as the closest thing the world has to a vaccine, paving the way for the breakthrough drug to reach millions of people in the hardest-hit countries. asserted
drug → approve → countries
The United Nations believes Lenacapavir, which is made by US pharmaceutical giant Gilead Sciences, could be key to reaching the goal of ending the Aids epidemic by 2030. uncertain
which → believe → 2030
The generic, developed by India’s Dr Reddy’s Laboratories, will cost just $40 per person per year and be made available in 120 low- and middle-income countries under an existing partnership agreement brokered by global health initative Unitaid, the Clinton Health Access Initiative and Wits RHI, a health research institute in Africa. asserted
generic → develop → Africa
Zambia is expected to be the first country to get the supplies. asserted
Zambia → expect → supplies
Carmen Pérez Casas, HIV lead at Unitaid, told The Independent that the more people who acquire HIV, the harder the epidemic is to control, “so we absolutely need to cut the number of infections. asserted
we → tell → infections
This tool really holds a promise.” asserted
tool → hold → promise
She added that with no vaccine yet, this is “the closest we are to having an opportunity”. asserted
we → add → opportunity
But the generic required FDA approval to be distributed, which was achieved in record time. asserted
which → require → time
Today’s announcement comes around 16 months after the FDA approved the original version. asserted
FDA → come → version
Life-saving antiretroviral therapy, for example, was available in the West for a full decade before it reached sub-Saharan Africa, a delay that cost countless lives. asserted
that → save → lives
“It has never been so fast that the generic product comes so soon after the originator is approved,” Ms Pérez Casas continued. asserted
Casas → come → ?
“In less than 16 months since Gilead, the originator product, was approved by the US FDA, we have today a lenacapavir injectable manufactured by the generics at a $40 price that has received FDA approval as well,” she said. asserted
she → approve → approval
“Normally, you require around a decade.” asserted
you → require → decade
The approval comes at a critical moment. asserted
approval → come → moment
Around 1.2 million people are infected with HIV every year, many in low-income countries. asserted
people → infect → countries
At the start of 2025 the world was on track to end the Aids pandemic by 2030, but unprecedented aid cuts from the US, the UK and other European countries have caused the biggest ever disruption to the HIV response, from testing to treatment and prevention. asserted
cuts → end → treatment
The Independent’s own modelling found that if the cuts continue, there could be millions more deaths and infections. uncertain
cuts → find → ?
Until now Gilead has been the sole supplier of lenacapavir, selling only small quantities at cheaper prices to poorer nations, with demand far outstripping supply. asserted
demand → sell → supply
Gilead granted voluntary licences to six generic manufacturers, and Unitaid selected Dr Reddy’s from among them to bring an affordable version to market as quickly as possible. asserted
Unitaid → grant → market
“With Gilead alone, there is no way we can meet that demand because they are not producing enough,” Ms Pérez Casas said. asserted
Casas → be → enough
The US government and the Global Fund have committed to reaching three million by 2028. asserted
government → commit → 2028
Experts estimate around 20 million people need to be on PrEP to bring the epidemic under control, ideally half of them on the injection. asserted
people → estimate → injection
So far, according to Unitaid, 175,000 people have received one dose of lenacapavir. uncertain
people → accord → lenacapavir
The Independent travelled to Eswatini where the jabs were being rolled out - there clinicians said they had already run out and demand was high. asserted
demand → travel → Eswatini
FDA approval is crucial because, under rules dating back to the early 2000s, antiretrovirals bought with US funding must be approved by the US regulator, even if they are never sold in America. asserted
they → date → America
It also allows other countries, and the World Health Organization, to fast-track their own approvals. asserted
countries → allow → approvals
Zambia is expected to be among the first countries to receive the generic before the end of 2026, with Unitaid hoping supplies arrive by World Aids Day on 1 December. asserted
supplies → expect → December
But the deal still leaves gaps. asserted
deal → leave → gaps
The 120 countries covered by Gilead’s licences exclude nations accounting for at least 10 per cent of global infections, some with rising epidemics, including Brazil, where part of the clinical trials took place. asserted
part → cover → place
“We hope that in near future, yes, there could be a possibility for those countries to also access the low-cost generics,” Ms Pérez Casas said. uncertain
Casas → hope → generics
This article has been produced as part of The Independent’s Rethinking Global Aid project asserted
article → produce → project
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support